Androgen dynamics and serum PSA in patients treated with abiraterone acetate
Authors:
Open Access
- 18 March 2014
- journal article
- research article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 17 (2) , 192-198
Abstract
Background: Methods: Results: Conclusions:Keywords
This publication has 27 references indexed in Scilit:
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in BoneJournal of Clinical Oncology, 2012
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic ResponseClinical Cancer Research, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- CYP17 polymorphisms and prostate cancer outcomesThe Prostate, 2010
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2010
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone AcetateJournal of Clinical Oncology, 2010
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole TherapyJournal of Clinical Oncology, 2010
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- Association of a CYP17 Polymorphism with Overall Survival in Caucasian Patients with Androgen-Independent Prostate CancerUrology, 2007